View all the latest information in lymphoma and CLL, arranged by trials and clinical studies. Listed below are recently added trial updates .
LyMa-101 trial update: Obinutuzumab for the treatment of mantle cell lymphoma
Summary of the updated results from the phase II LyMA-101 trial evaluating obinutuzumab plus high-dose cytarabine for the...
New chemotherapy-free approaches for the treatment of lymphoid malignancies
At the 15th International Conference on Malignant Lymphoma, the Lymphoma Hub Satellite Symposium highlighted recent advances...
Pembrolizumab receives FDA approval for extended indications in classical Hodgkin lymphoma
FDA extends indication for pembrolizumab as a monotherapy for adult and pediatric patients with cHL.
FDA grants priority review to second-line pembrolizumab for the treatment of R/R Hodgkin lymphoma
On July 9, 2020, the U.S. Food and Drug Administration (FDA) granted priority review to pembrolizumab...
KTE-X19 receives CHMP positive opinion for the treatment of patients with R/R MCL
On October 16, 2020, brexucabtagene autoleucel received positive opinion from the EMA CHMP for the treatment of adult...
Brexucabtagene autoleucel receives FDA approval for the treatment of relapsed/refractory mantle cell lymphoma
On July 24, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval...
Lymphodepletion optimization for CAR T-cell therapy
A summary of the talk by Elizabeth Budde at the eighth annual meeting of the SOHO regarding the optimization of lymphodepletion protocols.
CAR T-cell therapy limitations and strategies to overcome them from ASCO and EHA 2020
In recent years, cancer immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy, have shown good...
a
AATT
AETHERA
AHL 2011
AIM
ALCANZA
ALEXANDER
ALLIANCE
Alliance A041202
ALPHA
ASCEND
ASPEN
AUGMENT
b
BELIEF
BELINDA
BLAST
BRIGHT
c
CALGB-50303
CALGB-50403
CALGB-50901
CALM
CAPTIVATE
CAVALLI
CC-122-NHL-001
CheckMate 205
CHEMO-T
CHRONOS-3
CITADEL-101
CLARITY
CLL10
CLL12
CLL14
CLL2-GIVe
CLL8
CLOVER-1
COMPLEMENT A+B
CORAL
d
DAWN
DSHNHL 2006-1B/ACT-2
DSHNHL R3
DUO
DURABILITY
DYNAMO
e
E1912
ECHELON-1
ECHELON-2
ELARA
ELEVATE-TN
ELIANA
EMBOLDEN
f
FIL_FOLL12
FLASH
FLYER
FORERUNNER
g
GADOLIN
GALLIUM
GATHER
GO29365
GO29781
GOYA
h
HD12
HELIOS
HO105
HO130
HO75
i
IELSG32
IELSG36
iLLUMINATE
iNNOVATE
j
JCOG0203
JULIET
k
KEYNOTE-013
KEYNOTE-087
KEYNOTE-170
KEYNOTE-204
l
L-MIND
LNH-Pro-05
LUMIERE
LYM-3002
LyMa101
LYMRIT-37-01
m
MabCute
MAGNIFY
MAINTAIN
MAVORIC
MURANO
n
NCT00466531
NCT00496873
NCT00711828
NCT00848926
NCT01133743
NCT01282476
NCT01307605
NCT01403636
NCT01582776
NCT01626352
NCT01685008
NCT01685892
NCT01799889
NCT01818908
NCT01855750
NCT01865617
NCT01897012
NCT01973387
NCT01992653
NCT02006485
NCT02243436
NCT02260804
NCT02343120
NCT02362997
NCT02413489
NCT02535247
NCT02535286
NCT02572167
NCT02631577
NCT02730299
NCT02756897
NCT02776813
NCT03019666
NCT03057795
NCT03206970
NCT03207256
NCT03269669
NCT03502629
NCT03571568
NCT04030195
NCT04052997
o
OAsIs
ORIENT-1
p
PALL
PARMA
PETReA
PHILEMON
PILOT
PIVOTAL
PRECIS
PRIMA
PRIMO
r
RAY
RE-MIND
REFLECTIONS B3281006
RELEVANCE
RELY-30
REMARC
REMoDL-B
RESONATE
RESONATE-2
ROBUST
ROMULUS
s
SABRINA
SADAL
SCHOLAR-1
Smart Start
SWOG-9704
t
T-Cell Project
TRANSCEND WORLD
TRANSCEND-CLL-004
TRANSCEND-NHL-001
TRANSCEND-OUTREACH-007
TRANSFORM
Transplant BRaVE
u
UNITY-CLL
UNITY-NHL
v
VIsion/HO141
z
ZUMA-1
ZUMA-2
ZUMA-5
ZUMA-7
